Datassential Names Pascal Hartwig General Manager of EMEA, Releases First-Annual Top Chains in Europe Report
Datassential, the leading global food and beverage intelligence platform, announced the appointment of Pascal Hartwig as General Manager of EMEA.
This expansion is part of Datassential's ongoing strategy to shape the future of food and beverage intelligence with a unified platform that delivers scale, speed, and precision for every customer type across the foodservice industry, including operators, manufacturers, distributors and suppliers. Hartwig’s leadership marks a pivotal step in positioning Datassential as the definitive source of truth in Europe, the Middle East, and Africa — building on its North American dominance to establish a stronger global footprint.
Pascal was previously the Chief Product Officer at BeZero Carbon, and held senior leadership roles at S&P Global Market Intelligence. During his career, Pascal has established a strong track record in financial services, data solutions, product innovation and delivering value to customers.
“Pascal's appointment reflects Datassential's commitment to serve the global food and beverage industry,” said Jim Emling, CEO of Datassential. “With Pascal onboard, it accelerates our ability to scale internationally, ensuring that companies across the region gain access to the same transformative insights that have redefined success in the U.S.”
Pascal will lead Datassential’s expansion across EMEA, overseeing strategy and operations to deliver unparalleled food and beverage intelligence solutions to the European market.
“Datassential has built a unique platform that translates food and beverage insights into actionable sales intelligence that pinpoints whitespace, prioritizes high‑value accounts, and accelerates pipeline and revenue,” Hartwig said. “I am excited to lead the company’s expansion in EMEA and partner with brands and operators across the region to sharpen go‑to‑market execution, shorten sales cycles, and unlock new opportunities for growth.”
Alongside this leadership expansion, Datassential released Top Chains in Europe — a first-of-its-kind report ranking the 75 biggest foodservice chains in France, the UK, Spain, Germany, and Italy. Get your copy here.
About Datassential
Datassential is the food and beverage industry’s trusted insights and intelligence partner, helping brands make smarter decisions since 2001. Following its acquisition of Brizo FoodMetrics, Datassential now offers the largest and most complete sales intelligence solution in foodservice.
Over 90% of the biggest names in foodservice, including Danone, France Boissons, Pernod Ricard, Bacardi, Red Bull, Lactalis Italia, Vandemoortele Europe and Sysco, rely on Datassential to stay ahead of what’s next.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013748149/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FoodChain ID Certifies Mulino Bianco’s Buongrano to Regenerative Agriculture (RGN) Standard13.10.2025 13:00:00 CEST | Press release
Italy’s leading baked-goods company, a Barilla Group brand, introduces the country’s first cookie certified with 100% regenerative soft wheat flour. FoodChain ID today announced that Mulino Bianco’s Buongrano has been certified to the FoodChain ID Regenerative Agriculture (RGN) Certification, marking Italy’s first bakery brand to introduce a cookie certified with 100% regenerative soft wheat flour.1 The certification provides independent verification of regenerative outcomes and will be communicated on-pack via the FoodChain ID RGN mark, helping consumers identify products sourced from farms advancing soil health, biodiversity and climate resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013488950/en/ FoodChain ID today announced that Mulino Bianco’s Buongrano has been certified to the FoodChain ID Regenerative Agriculture (RGN) Certification, marking Italy’s first bakery brand to introduce a cookie certified wit
World FZO Concludes Its 11th World Congress in Hainan13.10.2025 12:14:00 CEST | Press release
More than 1,200 Participants from 70 Countries and 16 High-Level Ministerial Delegations The World Free Zones Organization concluded its 11th Annual World Congress in Hainan, hosted from October 10-12. The event attracted more than 1,200 participants from 70 countries, along with 16 high-level ministerial delegations and representatives of international economic and trade organisations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013845341/en/ HE Miguel Lecaro, Ambassador of the Republic of Panama to China, receiving the flag from H.E. Dr. Mohammed Al Zarooni (Photo: AETOSWire) The final day featured the Annual General Assembly meeting, during which a set of strategic resolutions aimed at enhancing the organisation’s operational framework and strengthening its global network of free zones was adopted. Elections were also held for the World FZO Board of Directors for a new term. The closing ceremony was attended by Liu
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA13.10.2025 12:00:00 CEST | Press release
Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory mantle cell lymphoma (MCL)BeOne to participate in Project Orbis program, supporting efforts to rapidly advance global access BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Additionally, the FDA has accepted BeOne’s request for participation in Project Orbis, an initiative that provides a framework for concurrent submission and review of oncology products among participating global health authorities. “Breakthrough Therapy Designation is reserved for medicines with the potential to transform outcomes for pati
I-Pulse Welcomes Codelco as Strategic Investor13.10.2025 07:00:00 CEST | Press release
World’s Largest Copper Producer Joins Mining Majors Backing I-Pulse TechnologyI-Pulse Employs High Pulsed Power to Create Disruptive Solutions for Resource Discovery, Mining, Manufacturing, Agriculture and Geothermal Energy I-Pulse Co-Founder, Chairman and CEO Robert Friedland and Laurent Frescaline, Co-Founder and Chief Technology Officer, are pleased to welcome Codelco as the company’s latest strategic investor and key partner in the development and commercialization of its disruptive pulsed power technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251012216264/en/ I-Pulse Co-Founder Chairman and CEO Robert Friedland and Codelco Chairman Máximo Pacheco Codelco, the world’s largest copper miner, will provide capital and real-world experience to accelerate the commercialization of I-Pulse’s breakthrough innovations for drilling, continuous underground mining, tunnelling and rock crushing. Codelco joins world leading
AdvanCell to Present Promising Clinical Trial Results of ADVC001, a Novel Lead-212-based PSMA-targeted Alpha Therapy for Prostate Cancer, at ESMO 202513.10.2025 01:31:00 CEST | Press release
Results from the Phase 1b dose escalation of the TheraPb Phase 1/2 trial are the first clinical data for a Lead-212 (212Pb)-based-PSMA radioligand therapy The abstract presents a favorable safety profile for 212Pb-ADVC001 and promising anti-tumor activity, underscoring its potential to enhance therapeutic options for patients with metastatic prostate cancer The upcoming presentation at ESMO will feature updated safety and efficacy results from all seven Phase 1b treatment cohorts AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, announces a presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Berlin, Germany, from October 17-21, 2025. The presentation will feature promising results from the Phase 1b dose escalation of the Phase 1/2 TheraPb study, evaluating ADVC001, a Lead-212-based PSMA-targeted alpha therapy, in metastatic castration-resistant prostate cancer (mCRPC). This will be t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom